Conquering The Final Frontier In Lung Transplantation - Mesenchymal Stromal Cell Therapy For Chronic Lung Allograft Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$1,887,790.00
Summary
Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.
I am a pulmonary physician-gene therapist persuing new therapies for pulmonary vascular disease, lung cancer and mesothelioma, COPD and lung transplant rejection
Monitoring Of Leucocyte Cytokine-chemokines To Improve Morbidity And Rejection Rates In Lung Transplant Patients
Funder
National Health and Medical Research Council
Funding Amount
$373,973.00
Summary
Lung transplantation has become established therapy for many serious lung diseases. The early success rate is now very good, but at five years after transplant the survival rate is only around 60%. This problem is largely due to chronic graft failue as a result of chronic rejection or bronchiolitis obliterans syndrome. This project will specifically investigate the causes of BOS and thereby provide new information on how we may best treat this problem. An improvement in this area is critical.